Salute e Benessere
Chiesi Group's new Biotech Center of Excellence brings the future of medicine to Parma
This adaptability ensures Chiesi will remain at the forefront of medical trends, while the Center's capability will support the production of small and large batches, and both experimental and approved drugs to facilitate a seamless transition from clinical trials to commercial manufacturing. The new center will enhance Chiesi's focus areas in respiratory, special care treatments, and rare diseases, thereby strengthening its overall strategic position.
To be more and more competitive in today's pharmaceutical landscape, Chiesi is placing a . The decision to establish a center of excellence to produce biologic drugs in Italy is even more significant in the . The report underscores the by focusing on upskilling, research, and development, and addressing regulatory hurdles.
The Biotech Center of Excellence will help address healthcare challenges, aiming for a more resilient and sustainable system. Chiesi seeks to align with recent biopharmaceutical advancements, and increase production in Europe , attracting international talent and investment, and creating global partnerships. This project supports Chiesi's growth in R&D, with over 20% of turnover allocated to it, .
said .
said .
The opening event celebrated Chiesi's dedication to research in Italy , highlighting ongoing investments that create value and high-quality jobs. Of the approximately €400 million that Chiesi will invest, €120 million is allocated to infrastructure, while €260 million will be spent over the long term (2023–2030) on materials, innovative technologies, skills development, and training.
The Center of Excellence will employ , with current technical activities involving 60 people, expected to grow to over 80 by the end of 2025. The new therapeutic opportunities from the Biotech Center will position Chiesi as a major player in the rapidly growing biopharmaceutical sector.
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy , the US, and France , Chiesi's commitment to creating shared value for society is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we're part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With over 85 years of experience, Chiesi is headquartered in Parma ( Italy ), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group's research and development center in Parma works alongside 6 other important R&D hubs in France , the US, Canada , China , the UK, and Sweden . For further information please visit www.chiesi.com .
View original content: https://www.prnewswire.co.uk/news-releases/chiesi-groups-new-biotech-center-of-excellence-brings-the-future-of-medicine-to-parma-302275036.html